Evidence map›Paper›PMID 39294925›Full record

ArticleThe journal of pathology. Clinical research2024

Validation of a whole slide image management system for metabolic-associated steatohepatitis for clinical trials.

Hanna Pulaski, Shraddha S Mehta, Laryssa C Manigat, Stephanie Kaufman, Hypatia Hou, ILKe Nalbantoglu, Xuchen Zhang, Emily Curl, Ross Taliano, Tae Hun Kim and 9 more

Abstract readValidation Study
In one paragraph

Article in The journal of pathology. Clinical research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Association betweenWorld journal of hepatology · 2025
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Hanna PulaskiPathAI, Inc, Boston, MA, USA.ORCID 0000-0001-8092-0066
Shraddha S MehtaPathAI, Inc, Boston, MA, USA.
Laryssa C ManigatPathAI, Inc, Boston, MA, USA.
Stephanie KaufmanPathAI, Inc, Boston, MA, USA.
Hypatia HouPathAI, Inc, Boston, MA, USA.
ILKe NalbantogluDepartment of Pathology, Yale University School of Medicine, New Haven, CT, USA.
Xuchen ZhangDepartment of Pathology, Yale University School of Medicine, New Haven, CT, USA.
Emily CurlFoundation Medicine, Inc, Boston, MA, USA.
Ross TalianoDepartment of Pathology, Rhode Island Hospital, Providence, RI, USA.
Tae Hun KimPathology Medical Group of Riverside, Providence, RI, USA.
Michael TorbensonDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
Jonathan N GlickmanPathAI, Inc, Boston, MA, USA.
Murray B ResnickPathAI, Inc, Boston, MA, USA.
Neel PatelPathAI, Inc, Boston, MA, USA.
Cristin E TaylorPathAI, Inc, Boston, MA, USA.
Pierre BedossaLiverpat and University of Paris, Paris, France.
Michael C MontaltoPathAI, Inc, Boston, MA, USA.
Andrew H BeckPathAI, Inc, Boston, MA, USA.
Katy E WackPathAI, Inc, Boston, MA, USA.ORCID 0009-0008-7761-3637

Funding

PathAI, Inc
6 · The paper itself

Abstract

The gold standard for enrollment and endpoint assessment in metabolic dysfunction-associated steatosis clinical trials is histologic assessment of a liver biopsy performed on glass slides. However, obtaining the evaluations from several expert pathologists on glass is challenging, as shipping the slides around the country or around the world is time-consuming and comes with the hazards of slide breakage. This study demonstrated that pathologic assessment of disease activity in steatohepatitis, performed using digital images on the AISight whole slide image management system, yields results that are comparable to those obtained using glass slides. The accuracy of scoring for steatohepatitis (nonalcoholic fatty liver disease activity score ≥4 with ≥1 for each feature and absence of atypical features suggestive of other liver disease) performed on the system was evaluated against scoring conducted on glass slides. Both methods were assessed for overall percent agreement with a consensus "ground truth" score (defined as the median score of a panel of three pathologists' glass slides). Each case was also read by three different pathologists, once on glass and once digitally with a minimum 2-week washout period between the modalities. It was demonstrated that the average agreement across three pathologists of digital scoring with ground truth was noninferior to the average agreement of glass scoring with ground truth [noninferiority margin: -0.05; difference: -0.001; 95% CI: (-0.027, 0.026); and p < 0.0001]. For each pathologist, there was a similar average agreement of digital and glass reads with glass ground truth (pathologist A, 0.843 and 0.849; pathologist B, 0.633 and 0.605; and pathologist C, 0.755 and 0.780). Here, we demonstrate that the accuracy of digital reads for steatohepatitis using digital images is equivalent to glass reads in the context of a clinical trial for scoring using the Clinical Research Network scoring system.

Indexed as

Non-alcoholic Fatty Liver DiseaseBiopsyClinical Trials as TopicHumansImage Interpretation, Computer-AssistedLiverObserver VariationReproducibility of Resultsclinical trialsdigital pathologyMASHmetabolic‐associated steatohepatitisNASHnonalcoholic steatohepatitisvalidation

Identifiers

PMID39294925
PMCPMC11410674

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.